内镜下经鼻与显微镜下经蝶手术治疗复发和/或残余垂体腺瘤的比较
该系统评价与Meta分析检索1985—2015年PubMed文献,纳入21项研究,比较内镜与显微镜经蝶手术治疗复发/残余垂体腺瘤的结局。内镜组292例、显微镜组648例;内镜组肿瘤全切率53.5% vs 46.6%,内分泌缓解率53.0% vs 46.7%,视力改善率73.2% vs 49.6%。内镜组脑脊液漏与垂体功能减退发生率更高。
要点
- 内镜组肿瘤全切率53.5%,显微镜组46.6%,内镜仅轻度提高切除率。
- 内镜组视力改善率73.2%,显微镜组49.6%,内镜组改善更明显。
- 内镜组脑脊液漏与垂体功能减退发生率高于显微镜组。
核心结论
- Meta分析表明,内镜再手术治疗残余或复发腺瘤仅使切除率轻度提高,但所处理病例更大更复杂,直接比较可能产生误导。
- 最显著的变化是视力改善,同时风险轻度增加;复发或残余腺瘤再手术是安全有效的治疗选择。
研究设计与样本
- 系统评价与Meta分析,检索PubMed(1985—2015年)以识别内镜下经鼻与显微镜下经蝶切除残余或复发垂体腺瘤的手术系列。
- 共纳入21项研究,内镜组292例患者,显微镜组648例患者。
主要发现
- 内镜组病例更多为无功能腺瘤(P < 0.001)和大腺瘤(P < 0.001),海绵窦侵犯率更高(P = 0.012)。
- 肿瘤全切率内镜组为53.5%,显微镜组为46.6%。
- 内分泌缓解率内镜组为53.0%,显微镜组为46.7%。
- 视力改善率内镜组为73.2%,显微镜组为49.6%。
- 脑脊液漏和垂体功能减退在内镜组更高。
关键数值与推荐
- 内镜组肿瘤全切率53.5% vs 显微镜组46.6%。
- 内镜组内分泌缓解率53.0% vs 显微镜组46.7%。
- 内镜组视力改善率73.2% vs 显微镜组49.6%。
- 内镜组无功能腺瘤比例更高(P < 0.001)。
- 内镜组大腺瘤比例更高(P < 0.001)。
临床怎么用
- 原文结论认为复发或残余腺瘤再手术是安全有效的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Surgery for recurrent/residual pituitary adenomas is increasingly being performed through endoscopic surgery. Whether this new technology has altered the indications and outcomes of surgery is unknown. We conducted a systematic review and meta-analysis of published studies to compare the indications and outcomes between microscopic and endoscopic approaches. METHODS: A PubMed search was conducted (1985-2015) to identify surgical series of endoscopic endonasal and microscopic transsphenoidal resection of residual or recurrent pituitary adenomas. Data were extracted regarding tumor characteristics, surgical treatment, extent of resection, endocrine remission, visual outcome, and complications. RESULTS: Twenty-one studies met inclusion criteria. A total of 292 patients were in the endoscopic group, and 648 patients were in the microscopic group. Endoscopic cases were more likely nonfunctional (P < 0.001) macroadenomas (P < 0.001) with higher rates of cavernous sinus invasion (P = 0.012). The pooled rate of gross total tumor resection was 53.5% for the endoscopic group and 46.6% for the microscopic group. Endocrine remission was achieved in 53.0% and 46.7% of patients, and visual improvement occurred in 73.2% and 49.6% for the endoscopic and microscopic groups. Cerebrospinal fluid leak and pituitary insufficiency were higher in the endoscopic group. CONCLUSION: This meta-analysis indicates that the use of the endoscope to reoperate on residual or recurrent adenomas has only led to modest increases in resection rates. However, larger more complex cases are being tackled, so direct comparisons are misleading. The most dramatic change has been in visual improvement along with modest increases in risk. Reoperation for recurrent or residual adenomas is a safe and effective treatment option.
引用
- Esquenazi Y, Essayed WI, Singh H, et al. Endoscopic Endonasal Versus Microscopic Transsphenoidal Surgery for Recurrent and/or Residual Pituitary Adenomas. World Neurosurg. 2017. PMID: 28185971. doi:10.1016/j.wneu.2017.01.110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。